Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
Explore the latest research from McGill University that uncovers the demographic factors influencing melanoma risk, offering actionable insights for targeted prevention strategies.
Dermatology August 28th 2023
Medical Professionals Reference (MPR)
A 77-year-old man with a history of solar keratoses presents a progressively enlarging and darkening lesion on his right cheek, as observed by his wife over a year, with a dermoscopic examination revealing asymmetric pigmented follicular openings and greyish globules and dots.
Dermatology July 20th 2023
OMedLive
Discover how to navigate the evolving therapeutic landscape for advanced melanoma, with a focus on the latest immunotherapies, mitigation of treatment-associated adverse events, and patient-centric strategies to enhance shared decision-making and quality of life.
Dermatology June 27th 2023
OBR Oncology
The 2023 AACR meeting has seen a large number of clinical abstracts presented, demonstrating that science from the lab is moving to the clinic. Examples include an RNA vaccine from Moderna in combination with pembrolizumab in a neoadjuvant setting in patients with melanoma, and the AEGEAN trial, which looks at perioperative therapy in patients with lung cancer. The conference is also seeing a focus on more diverse speakers, including junior investigators. The field of mRNA cancer vaccines is evolving, with personalised vaccines being used to activate the immune system in combination with checkpoint inhibitors, resulting in positive results in some cancers. The conference is an opportunity to learn about new science, make new connections and collaborations, and gain a better understanding of how to push the field forward.
Oncology, Medical May 1st 2023
The New England Journal of Medicine
Event-free survival was significantly longer in patients with resectable stage III or IV melanoma who received pembrolizumab both before and after surgery than in those who received adjuvant pembrolizumab alone. New toxic effects were not discovered.
Dermatology March 6th 2023
ReachMD
Lack of Concordance Between Radiologic and Pathologic Responses in Neoadjuvant ICI Treatment of Melanoma: How Do I Assess Radiologic Progression? After taking part in this CME activity, medical oncologists, surgeons, dermatologists, oncology nurses, oncology pharmacists, and other members of the interprofessional team who manage patients with melanoma should be better able to:
Dermatology February 27th 2023